Figure 4From: Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patientsLocal recurrence rates according to the combined prognostic index (P21, CD44v6, and tumor location). High risk involves having two or three adverse risk factors (low tumor location, low P21 expression, and high CD44v6 expression). Low risk involves having no or one adverse risk factor.Back to article page